Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
November 01, 2022 08:30 ET
|
Processa Pharmaceuticals, Inc.
Next Generation Capecitabine (NGC) Dosage Regimens Have Been Identified In The Ongoing Phase 1B Trial With Potentially Better Safety And Efficacy Profiles Than Existing Chemotherapy These NGC...